<DOC>
	<DOCNO>NCT00440310</DOCNO>
	<brief_summary>The purpose study ass overall survival progression free survival patient treat Litx™ + chemotherapy versus chemotherapy alone treatment Colorectal Cancer recurrent liver metastasis , demonstrate safety Litx™ therapy . Litx™ consist light-activated drug , talaporfin sodium ( LS11 , Light Sciences Oncology , Bellevue , Washington ) , light generate device , compose light-emitting diode ( LEDs ) , energized power controller percutaneously place target tumor tissue inside body .</brief_summary>
	<brief_title>Phase 3 Trial Litx™ Plus Chemotherapy v . Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases</brief_title>
	<detailed_description>Randomized , stratify , two arm study : - Litx™ chemotherapy arm ( FOLFOX4 FOLFIRI ) - Chemotherapy arm ( FOLFOX4 FOLFIRI ) For patient progressed FOLFIRI , treat Litx™ plus FOLFOX4 versus FOLFOX4 alone ; patient progress FOLFOX , treat Litx™ plus FOLFIRI versus FOLFIRI alone . Stratification upon enrollment chemotherapy tumor sum long diameter ( SLD ) ( SLD &lt; 4 cm SLD ≥4 cm ≤7.5 cm ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>Patients recurrent metastatic liver lesion colorectal cancer progress either FOLFOX FOLFIRI Biopsy proven evidence colorectal cancer At least one liver lesion measure one dimension &gt; 10 mm spiral CT scan ( CT prefer MRI allow ) ECOG Performance Status 02 Life expectancy least 16 week At least 30 day must elapse since completion prior antineoplastic therapy patient must recover acute side effect day 0 Understanding ability sign write informed consent 18 year age Adequate hematologic , liver renal function evidence follow : WBC &gt; 2.5 × 10^9/L ; Platelet Count &gt; 100 × 10^9/L ; Hemoglobin &gt; 90 g/L ; Neutrophils &gt; 1.5 × 10^9/L ; PT PTT &lt; 1.5 Control ; SGOT , SGPT &lt; 5 × ULN ; GGT &lt; 5 × ULN ; Alkaline phosphatase &lt; 5 × ULN ; Bilirubin &lt; 3 × ULN ; Creatinine &lt; 1.5 × ULN Patients candidate complete surgical resection Patients receive bevacizumab ( Avastin® ) cetuximab ( Erbitux® ) within 30 day randomization . Use bevacizumab cetuximab prohibit participate study Patients would require total number 12 light source application three Litx™ experimental treatment ( 4 light source per treatment ) . Patients single measurable tumor great 7.5 cm organ Target lesion irradiate within 3 month randomization Patients tumor involvement great 50 % parenchyma liver Evidence major vessel invasion organ Patients noncolorectal cancer except adequately treat basal squamous cell skin cancer , adequately treated stage I II cancer patient diseasefree ≥ 3 year , cancer patient diseasefree ≥ 5 year Known sensitivity porphyrintype drug know history porphyria Pregnancy breastfeeding patient . A negative pregnancy test ( urine serum ) woman childbearing age require prior enrollment . A fertile patient must use effective contraception participation study Concurrent participation another clinical trial involve experimental treatment Any concurrent disease condition opinion investigator impair patient 's ability complete trial psychological , familial , sociological , geographical medical condition Principal Investigator 's opinion could compromise compliance objective procedure protocol obscure interpretation trial 's data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Liver neoplasm</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>MCRC</keyword>
	<keyword>Litx™</keyword>
	<keyword>LS11</keyword>
	<keyword>Colorectal cancer recurrent liver metastasis</keyword>
</DOC>